ArticleNature communications2021
The impact of the timely birth dose vaccine on the global elimination of hepatitis B.
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Vertical transmission of hepatitis B virus in the WHO African region: a systematic review and meta-analysis.The Lancet. Global health · 2025Pooled it
- Towards contextualized complex systems approaches to scaling-up hepatitis B birth-dose vaccination in the African region: a qualitative systematic review.Frontiers in public health · 2024Pooled it
- A systematic review reveals that African children of 15-17 years demonstrate low hepatitis B vaccine seroprotection rates.Scientific reports · 2023Pooled it
- Genomic characterization of hepatitis B virus from a vaccinated child in Nigeria suggests delayed neonatal immunoprophylaxis rather than vaccine escape: a case report.IJID regions · 2026Article
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Primary Cancer Prevention Through Vaccination: Advances, Challenges, and Global Perspectives.Health science reports · 2026Article
- Maternal preparedness for uptake of newborn hepatitis B immunoprophylaxis at birth: Implications for preventing mother-to-child transmission in resource-limited settings.IJID regions · 2026Article
- Feasibility of eliminating adult hepatitis B in Guangdong by 2030: A modeling study.Infectious Disease Modelling · 2026Article
- Willingness to accept the HBV vaccine and related factors: Administering the vaccination attitudes examination scale to Urban Vietnamese adults.PLOS global public health · 2026Article
- Article
- The Viral Hepatitis Prevention Board (VHPB) supports the continued recommendation for universal hepatitis B vaccination of all newborns within 24 hours of birth.Human vaccines & immunotherapeutics · 2025Article
- Real-World Study for Mother-To-Child Transmission of Hepatitis B in Guangdong Province, 2021-2023.Journal of viral hepatitis · 2025Article
- Nanoparticle-based systems for liver therapy: Overcoming fibrosis and enhancing drug efficacy.World journal of hepatology · 2025Review
- Prioritising viral hepatitis elimination to prevent hepatocellular carcinoma: A public health approach for effective preventive hepatology.JHEP reports : innovation in hepatology · 2025Review
- Epidemiology, Achievements, and Challenges in the Elimination of Hepatitis B in China.Journal of clinical and translational hepatology · 2025Review
- A 2024 global report on national policy, programmes, and progress towards hepatitis B elimination: findings from 33 hepatitis elimination profiles.The lancet. Gastroenterology & hepatology · 2025Review
- [Recent advances in epidemiology, prevention and treatment of hepatitis B in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025Article
- Article
- Global elimination of HBV: Is it really achievable?Journal of viral hepatitis · 2024Review
- Direct and indirect effects of hepatitis B vaccination in four low- and middle-income countries.Epidemics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In 2016 the World Health Organization set the goal of eliminating hepatitis B globally by 2030. Horizontal transmission has been greatly reduced in most countries by scaling up coverage of the infant HBV vaccine series, and vertical transmission is therefore becoming increasingly dominant. Here we show that scaling up timely hepatitis B birth dose vaccination to 90% of new-borns in 110 low- and middle-income countries by 2030 could prevent 710,000 (580,000 to 890,000) deaths in the 2020 to 2030 birth cohorts compared to status quo, with the greatest benefits in Africa. Maintaining this could lead to elimination by 2030 in the Americas, but not before 2059 in Africa. Drops in coverage due to disruptions in 2020 may lead to 15,000 additional deaths, mostly in South-East Asia and the Western Pacific. Delays in planned scale-up could lead to an additional 580,000 deaths globally in the 2020 to 2030 birth cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.